In:
BioMed Research International, Hindawi Limited, Vol. 2015 ( 2015), p. 1-11
Abstract:
Background . We examined (1) patient characteristics and disease-modifying drug (DMD) exposure in late-onset (LOMS, ≥50 years at symptom onset) versus adult-onset (AOMS, 18– 〈 50 years) MS and (2) the association between interferon-beta (IFN β ) and disability progression in older relapsing-onset MS adults (≥50 years). Methods . This retrospective study (1980–2004, British Columbia, Canada) included 358 LOMS and 5627 AOMS patients. IFN β -treated relapsing-onset MS patients aged ≥50 (regardless of onset age, 90) were compared with 171 contemporary and 106 historical controls. Times to EDSS 6 from onset and from IFN β eligibility were examined using survival analyses. Results . LOMS patients (6%) were more likely to be male, with motor onset and a primary-progressive course, and exhibit faster progression and were less likely to take DMDs. Nonetheless, 57% were relapsing-onset, of which 31% were prescribed DMDs, most commonly IFN β . Among older relapsing-onset MS adults, no significant association between IFN β exposure and disability progression was found when either the contemporary (hazard ratio [HR]: 0.46; 95% CI: 0.18–1.22) or historical controls (HR: 0.54; 95% CI: 0.20–1.42) were considered. Conclusion . LOMS differed clinically from AOMS. One-third of older relapsing-onset MS patients were prescribed a DMD. IFN β exposure was not significantly associated with reduced disability in older MS patients.
Type of Medium:
Online Resource
ISSN:
2314-6133
,
2314-6141
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2015
detail.hit.zdb_id:
2698540-8
Permalink
